Basit öğe kaydını göster

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

dc.contributor.authorRidolfi, Antonia
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorArce, Christina H.
dc.contributor.authorLin, Chinjune
dc.contributor.authorBachelot, Thomas Denis
dc.contributor.authorCardoso, Fatima
dc.contributor.authorVillanueva, Cristian
dc.contributor.authorRoyce, Melanie
dc.contributor.authorCruz, Felipe
dc.contributor.authorDebled, Marc
dc.contributor.authorHegg, Roberto
dc.contributor.authorToyama, Tatsuya
dc.contributor.authorFalkson, Carla Isadora
dc.contributor.authorJeong, Joon
dc.contributor.authorSrimuninnimit, Vichien
dc.contributor.authorGradishar, William John
dc.contributor.authorAzevedo, Sergio J.
dc.date.accessioned2021-03-03T09:46:56Z
dc.date.available2021-03-03T09:46:56Z
dc.identifier.citationCardoso F., Villanueva C., Royce M., Cruz F., Debled M., Hegg R., Toyama T., Falkson C. I. , Jeong J., Srimuninnimit V., et al., "Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.", 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35
dc.identifier.othervv_1032021
dc.identifier.otherav_1ee33d31-1f1a-495a-b15f-bdec514203d5
dc.identifier.urihttp://hdl.handle.net/20.500.12627/25912
dc.identifier.urihttps://doi.org/10.1200/jco.2017.35.15_suppl.1010
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectDahili Tıp Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.titleEverolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume35
dc.contributor.firstauthorID151444


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster